The proinflammatory CXC-chemokines GRO-α/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids

International Journal of Colorectal Disease

Volumn 22, Issue 12, 2007, Pages 1421-1427

  Egesten, Arne ^a   Eliasson, Mette ^a   Olin, Anders I ^a   Erjefält, Jonas S ^a   Bjartell, Anders ^b,d   Sangfelt, Per ^c   Carlson, Marie ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemokines; Cortico steroids; GRO CXCL1; MIG CXCL9; Ulcerative colitis

Indexed keywords

ALPHA CHEMOKINE; CORTICOSTEROID; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; ENEMA; INTERLEUKIN 8; MESALAZINE; PREDCLYSMA; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; GRANULOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SUBMUCOSA; TREATMENT DURATION; ULCERATIVE COLITIS;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CXCL1; CHEMOKINE CXCL10; CHEMOKINE CXCL9; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; DOWN-REGULATION; ENEMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; MALE; MIDDLE AGED; PERFUSION; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 35148823163     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-007-0370-3     Document Type: Article

References (31)

1. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429
2. Elliott SN, Wallace JL (1998) Neutrophil-mediated gastrointestinal injury. Can J Gastroenterol 12:559-568
3. Egesten A, Andersson P, Persson T (2002) Eosinophils in gastrointestinal inflammation: From innocent bystanders to offenders. Scand J Gastroenterol 37:1117-1125
4. Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ (1998) Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 4:285-290
5. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113:1490-1497
6. Baggiolini M (2001) Chemokines in pathology and medicine. J Intern Med 250:91-104
7. Luster AD (2001) Chemokines regulate lymphocyte homing to the intestinal mucosa. Gastroenterology 120:291-294
8. Wen DZ, Rowland A, Derynck R (1989) Expression and secretion of gro/MGSA by stimulated human endothelial cells. EMBO J 8:1761-1766
9. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162:3549-3558
10. Persson-Dajotoy T, Andersson P, Bjartell A, Calafat J, Egesten A (2003) Expression and production of the CXC chemokine growth-related oncogene-alpha by human eosinophils. J Immunol 170:5309-5316
11. Jinquan T, Jing C, Jacobi HH, Reimert CM, Millner A, Quan S, Hansen JB, Dissing S, Malling HJ, Skov PS, Poulsen LK (2000) CXCR3 expression and activation of eosinophils: Role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. J Immunol 165:1548-1556
12. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM (2000) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165:5269-5277
13. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M (2001) Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107:53-63
14. -CXC chemokines display defensin-like antimicrobial activity. J Immunol 167:623-627
15. Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228-1233
16. Sangfelt P, Carlson M, Thorn M, Lööf L, Raab Y (2001) Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol 96:1085-1090
17. Binder V (1979) A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol 5:627-632
18. Truelove SC, Richards WC (1956) Biopsy studies in ulcerative colitis. Br Med J 1:1315-13188
19. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-229
20. Sangfelt P, Carlson M, Thorn M, Xu S, Loof L, Raab Y (2002) Local release of human neutrophil lipocalin (HNL), IL-8, and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis. Dig Dis Sci 47:2064-2069
21. Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP, Sanderson IR (1999) Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: Evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 94:704-712
22. Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, Campieri M, Baggiolini M (1999) Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155:331-336
23. Borregaard N, Cowland JB (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89:3503-3521
24. Egesten A, Eliasson M, Johansson HM, Olin AI, Mörgelin M, Mueller A, Pease JE, Frick IM, Björck L (2007) The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J Infect Dis 195:684-693
25. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI (1992) Characterization of two high affinity human interleukin-8 receptors. J Biol Chem 267:16283-16287
26. Ahuja SK, Murphy PM (1996) The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 271:20545-20550
27. Loukinova E, Dong G, Enamorado-Ayalya I, Thomas GR, Chen Z, Schreiber H, Van Waes C (2000) Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19:3477-3486
28. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM (2004) Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172:2853-2860
29. Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S, Dubinett SM, Strieter RM (2006) CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 176:1456-1464
30. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, Harris NL, Junt T, Odermatt B, Clavien PA, Pircher H, Akira S, Hengartner H, Zinkernagel RM (2006) Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 116:2456-2463
31. Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, Jin Q, White JR, Lee JM, Goodman RB, Hagen TR, Kajikawa O, Marshall LA, Hay DW, Sarau HM (2002) A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 169:6435-6444